SSX family member 2BGenealiases: CT5.2 · CT5.2b · HOM-MEL-40 · SSX
Q-omics provides the consensus-scored SSX2B profile across patient tissues and cancer cell-line models. SSX2B expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SSX2B is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, SSX2B RNA expression shows 4,194 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LIHC, and STAD as cancer lineages where SSX2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSX2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSX2B survival associations across molecular data types. SSX2B RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSX2B RNA expression–survival associations across cancer types. High SSX2B expression shows unfavorable associations in KIRC, KICH, KIRP, OV, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SSX2B RNA expression.
This table summarizes SSX2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SSX2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSX2B shows higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher SSX2B RNA expression in tumor versus normal tissue (log2 FC = +0.031, t-test p = .005).
This table shows molecular features associated with SSX2B in patient tissues and cancer cell lines. In patient samples, SSX2B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SSX2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
